345 related articles for article (PubMed ID: 37175823)
1. Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases.
Ahmed R; Anam K; Ahmed H
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175823
[TBL] [Abstract][Full Text] [Related]
2. Targeting galectin-driven regulatory circuits in cancer and fibrosis.
Mariño KV; Cagnoni AJ; Croci DO; Rabinovich GA
Nat Rev Drug Discov; 2023 Apr; 22(4):295-316. PubMed ID: 36759557
[TBL] [Abstract][Full Text] [Related]
3. Galectins-3 and -7, but not galectin-1, play a role in re-epithelialization of wounds.
Cao Z; Said N; Amin S; Wu HK; Bruce A; Garate M; Hsu DK; Kuwabara I; Liu FT; Panjwani N
J Biol Chem; 2002 Nov; 277(44):42299-305. PubMed ID: 12194966
[TBL] [Abstract][Full Text] [Related]
4. The Role of Galectin-3 in Retinal Degeneration and Other Ocular Diseases: A Potential Novel Biomarker and Therapeutic Target.
Zhou Z; Feng Z; Sun X; Wang Y; Dou G
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958500
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of galectin-3 in the nucleus and cytoplasm.
Haudek KC; Spronk KJ; Voss PG; Patterson RJ; Wang JL; Arnoys EJ
Biochim Biophys Acta; 2010 Feb; 1800(2):181-9. PubMed ID: 19616076
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level.
Ma S; Li S; Lv R; Hou X; Nie S; Yin Q
J Diabetes Investig; 2020 Sep; 11(5):1295-1302. PubMed ID: 32196999
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 regulates inflammasome activation in cholestatic liver injury.
Tian J; Yang G; Chen HY; Hsu DK; Tomilov A; Olson KA; Dehnad A; Fish SR; Cortopassi G; Zhao B; Liu FT; Gershwin ME; Török NJ; Jiang JX
FASEB J; 2016 Dec; 30(12):4202-4213. PubMed ID: 27630169
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Galectin-1 and Galectin-3 in Autoimmune Diseases.
He YS; Hu YQ; Xiang K; Chen Y; Feng YT; Yin KJ; Huang JX; Wang J; Wu ZD; Wang GH; Pan HF
Curr Pharm Des; 2022; 28(1):36-45. PubMed ID: 34579628
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.
Ahmed H; Banerjee PP; Vasta GR
Biochem Biophys Res Commun; 2007 Jun; 358(1):241-6. PubMed ID: 17481580
[TBL] [Abstract][Full Text] [Related]
10. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
[TBL] [Abstract][Full Text] [Related]
11. Small Endogeneous Peptide Mitigates Myocardial Remodeling in a Mouse Model of Cardioselective Galectin-3 Overexpression.
Sonkawade SD; Pokharel S; Karthikeyan B; Kim M; Xu S; Kc K; Sexton S; Catalfamo K; Spernyak JA; Sharma UC
Circ Heart Fail; 2021 Sep; 14(9):e008510. PubMed ID: 34415177
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance.
Li P; Liu S; Lu M; Bandyopadhyay G; Oh D; Imamura T; Johnson AMF; Sears D; Shen Z; Cui B; Kong L; Hou S; Liang X; Iovino S; Watkins SM; Ying W; Osborn O; Wollam J; Brenner M; Olefsky JM
Cell; 2016 Nov; 167(4):973-984.e12. PubMed ID: 27814523
[TBL] [Abstract][Full Text] [Related]
13. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses.
Hsu DK; Yang RY; Pan Z; Yu L; Salomon DR; Fung-Leung WP; Liu FT
Am J Pathol; 2000 Mar; 156(3):1073-83. PubMed ID: 10702423
[TBL] [Abstract][Full Text] [Related]
14. Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice.
Nomoto K; Tsuneyama K; Abdel Aziz HO; Takahashi H; Murai Y; Cui ZG; Fujimoto M; Kato I; Hiraga K; Hsu DK; Liu FT; Takano Y
J Pathol; 2006 Dec; 210(4):469-77. PubMed ID: 17029217
[TBL] [Abstract][Full Text] [Related]
15. Biophysical and Structural Characterization of the Interaction between Human Galectin-3 and the Lipopolysaccharide from
Pirone L; Lenza MP; Di Gaetano S; Capasso D; Filocaso M; Russo R; Di Carluccio C; Saviano M; Silipo A; Pedone E
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474141
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 mediates survival and apoptosis pathways during Trypanosoma cruzi-host cell interplay.
Chain MO; Paiva CAM; Maciel IO; Neto AN; Castro VF; Oliveira CP; Mendonça BDS; Nestal de Moraes G; Reis SAD; Carvalho MA; De-Melo LDB
Exp Parasitol; 2020 Sep; 216():107932. PubMed ID: 32535113
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 facilitates cell-to-cell HIV-1 transmission by altering the composition of membrane lipid rafts in CD4 T cells.
Wang SF; Hung YH; Tsao CH; Chiang CY; Teoh PG; Chiang ML; Lin WH; Hsu DK; Jan HM; Lin HC; Lin CH; Liu FT; Chen HY
Glycobiology; 2022 Aug; 32(9):760-777. PubMed ID: 35789267
[TBL] [Abstract][Full Text] [Related]
18. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding.
Nita-Lazar M; Banerjee A; Feng C; Amin MN; Frieman MB; Chen WH; Cross AS; Wang LX; Vasta GR
Mol Immunol; 2015 May; 65(1):1-16. PubMed ID: 25597246
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 modulation of T-cell activation: mechanisms of membrane remodelling.
Gilson RC; Gunasinghe SD; Johannes L; Gaus K
Prog Lipid Res; 2019 Oct; 76():101010. PubMed ID: 31682868
[TBL] [Abstract][Full Text] [Related]
20. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (
Varasteh Z; De Rose F; Mohanta S; Li Y; Zhang X; Miritsch B; Scafetta G; Yin C; Sager HB; Glasl S; Gorpas D; Habenicht AJR; Ntziachristos V; Weber WA; Bartolazzi A; Schwaiger M; D'Alessandria C
Theranostics; 2021; 11(4):1864-1876. PubMed ID: 33408786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
